SEQENS
Brandon Kidd is an accomplished business development and investment professional with extensive experience in multiple sectors, including pharmaceuticals, consumer goods, and real estate. Currently serving as the Director of Business Development & Sales at SEQENS since May 2024, Brandon previously held several key leadership roles, such as Chief Business Development Officer at Benuvia Operations, LLC, and Managing Director at Mile High Labs. Brandon's career also includes significant positions at Green Capital, Harte Realty S.A., KiddCo International, and Newmark Knight Frank, showcasing a strong background in investment management and consulting. Brandon holds a BA in International Relations and Spanish from the University of Colorado Boulder and has pursued additional education in Costa Rica and Texas.
This person is not in any offices
SEQENS
SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. The group generates a revenue of 1.4 MM€ and operates 24 manufacturing plants and 10 R&D centers in Europe, North America and Asia. 3,400 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers. SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.